10-Q
Quarterly Report
DRUGS MADE IN AMERICA ACQUISITION II CORP. DMII DMIIR DMIIU
0001213900-26-056651
- Filed
- May 14, 2026 12:00 AM ET
- Period of report
- —
On SEC.gov
Financials in this filing
| Metric | Period | Value |
|---|---|---|
| Shares Outstanding | Q1 2026 · May 14, 2026 | 63.7M sh |
| Operating Cash Flow | Q1 2026 · Mar 31, 2026 | −$102.5K |
| Operating Cash Flow | Q1 2026 · Mar 31, 2025 | −$10.04K |
| Short Term Debt | Q1 2026 · Mar 31, 2026 | $450K |
| Cash And Equivalents | Q1 2026 · Mar 31, 2026 | $347.72K |
| Cash And Equivalents | Q1 2026 · Dec 31, 2025 | $223 |
| Stockholders Equity | Q1 2026 · Mar 31, 2026 | −$17.81M |
| Stockholders Equity | Q1 2026 · Dec 31, 2025 | −$17.77M |
| Stockholders Equity | Q1 2026 · Mar 31, 2025 | −$176.05K |
| Stockholders Equity | Q1 2026 · Dec 31, 2024 | −$116.72K |
| Current Liabilities | Q1 2026 · Mar 31, 2026 | $666.29K |
| Current Liabilities | Q1 2026 · Dec 31, 2025 | $300.86K |
| Total Liabilities | Q1 2026 · Mar 31, 2026 | $18.17M |
| Total Liabilities | Q1 2026 · Dec 31, 2025 | $17.8M |
| Current Assets | Q1 2026 · Mar 31, 2026 | $351.76K |
| Current Assets | Q1 2026 · Dec 31, 2025 | $26.04K |
| Total Assets | Q1 2026 · Mar 31, 2026 | $509.73M |
| Total Assets | Q1 2026 · Dec 31, 2025 | $504.96M |
| Sga Expense | Q1 2026 · Mar 31, 2026 | $132.03K |
| Sga Expense | Q1 2026 · Mar 31, 2025 | $59.33K |
| Net Income | Q1 2026 · Mar 31, 2026 | $4.34M |
| Net Income | Q1 2026 · Mar 31, 2025 | −$59.33K |
| Operating Income | Q1 2026 · Mar 31, 2026 | −$132.03K |
| Operating Income | Q1 2026 · Mar 31, 2025 | −$59.33K |